<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">XYLOMETAZOLINE HYDROCHLORIDE</span><br/>(zye-loe-met-az'oh-leen)<br/><span class="topboxtradename">Neo-Synephrine II, </span><span class="topboxtradename">Otrivin<br/></span><b>Classifications:</b> <span class="classification">nasal decongestant</span>; <span class="classification">vasoconstrictor</span><br/><b>Prototype: </b>Naphazoline<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.05%, 0.1% nasal solution</p>
<h1><a name="action">Actions</a></h1>
<p>Markedly constricts dilated arterioles of nasal membrane. Has little or no beta-adrenergic activity. Structurally related
         to naphazoline.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Decreases fluid exudate and mucosal engorgement associated with rhinitis and may open up obstructed eustachian ostia in patient
         with ear inflammation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Temporary relief of nasal congestion associated with common cold, sinusitis, acute and chronic rhinitis, and hay fever and
         other allergies.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Sensitivity to adrenergic substances; angle-closure glaucoma; concurrent therapy with MAO inhibitors or tricyclic antidepressants;
         lactation, and infants. Safe use during pregnancy (category C) is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypertension; hyperthyroidism; heart disease, including angina; advanced arteriosclerosis, older adults, and children.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Nasal Congestion</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Nasal</span> 12 sprays or 12 drops of 0.1% solution in each nostril q810h (max: 3 doses/d)<br/><span class="rdage">Child:</span> <span class="rdroute">Nasal</span> mo, 1 drop of 0.05% solution in each nostril q6h  (max: 3 doses/d); <i>6 mo12 y</i>, 1 spray or 23 drops of 0.05% solution in each nostril q810h (max: 3 doses/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Instillation</span><br/><ul>
<li>Have patient clear each nostril gently before administering spray or drops.</li>
<li>Spray: Do not shake container. Hold tube vertically (spray end up) so that solution is delivered in a fine spray. Head should
            be erect; spray into each nostril; 35 min later, clear (blow) nose thoroughly.
         </li>
<li>Drops: Patient should be in a lateral, head-low position to permit application of drops to lower nostril surface. Have patient
            remain in this position for 5 min, then apply drops to opposite nostril surface in same manner; or drops may be instilled
            with patient in reclining position with head tilted back as far as possible.
         </li>
<li>Store at 15°30° C (59°86° F) in a tight, light-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">All:</span> Usually mild and infrequent; local stinging, burning, dryness and ulceration, sneezing, headache, insomnia, drowsiness. <span class="typehead">With excessive use:</span> <span class="speceff-common">Rebound nasal congestion</span> and vasodilation, tremulousness, hypertension, palpitations, tachycardia, arrhythmia, somnolence, sedation, <span class="speceff-life">coma</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May cause increase BP with <b>guanethidine,</b> <b>methyldopa,</b> <span class="classification">mao inhibitors</span>; <span class="classification">phenothiazines</span> may decrease effectiveness of nasal decongestant. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 510 min. <span class="typehead">Duration:</span> 56 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Evaluate for development of rebound congestion (see <small>ADVERSE EFFECTS</small>).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Prevent contamination of nasal solution and spread of infection by rinsing dropper and tip of nasal spray in hot water after
            each use; restrict use to the individual patient.
         </li>
<li> 							Note: Prolonged use can cause rebound congestion and chemical rhinitis. Do <small> <small>NOT</small> </small> exceed prescribed dosage and report to physician if drug fails to provide relief within 34 d. 						
         </li>
<li>Do <small>NOT</small> self-medicate with OTC drugs, sprays, or drops without physician's approval.
         </li>
<li> 							Note: Excessive use by a child may lead to CNS depression. 						</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>